Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1

Oncotarget

Volumn 7, Issue 36, 2016, Pages 58111-58120

  Xie, Xiayang ^a,b   Tang, Shou Ching ^c,d   Cai, Yafei ^c   Pi, Wenhu ^c   Deng, Libin ^c   Wu, Guangyu ^c   Chavanieu, Alain ^e   Teng, Yong ^a,c  

^a AUGUSTA UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e UNIV MONTPELLIER   (France)

Author keywords

ARF1; Breast cancer; LM11; Metastasis; Zebrafish

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 1; ANTINEOPLASTIC AGENT; ARF NUCLEOTIDE BINDING SITE OPENER PROTEIN; CELL PROTEIN; GUANOSINE DIPHOSPHATE; LM 11; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CYTOHESIN-2; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; LM11 COMPOUND; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARF1 GENE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; EMBRYO; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; GENETIC ASSOCIATION; GOLGI COMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; LUNG METASTASIS; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; UPREGULATION; ZEBRA FISH; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL MOTION; CELL SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; GENE KNOCKDOWN; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MORTALITY; NONOBESE DIABETIC MOUSE; PATHOLOGY; RNA INTERFERENCE; SECONDARY; TISSUE MICROARRAY; TRANSGENIC ANIMAL; TUMOR CELL LINE;

ADP-RIBOSYLATION FACTOR 1; ANILINE COMPOUNDS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BENZIMIDAZOLES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; GOLGI APPARATUS; GTPASE-ACTIVATING PROTEINS; GUANOSINE DIPHOSPHATE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZEBRAFISH;

EID: 84988430449     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11185     Document Type: Article

References (50)

1. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell. 2006; 127:679-695.
2. Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, et al. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res. 2014; 16:440.
3. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2:563-572.
4. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147:275-292.
5. Nguyen DX, Massagué J. Genetic determinants of cancer metastasis. Nat Rev Genet. 2007; 8:341-352.
6. Clark J, Moore L, Krasinskas A, Battey J, Tamkun J, Kahn RA. Selective amplification of additional members of the ADP-ribosylation factor (ARF) family: cloning of additional human and Drosophila ARF-like genes. Proc Natl Acad Sci USA. 1993; 90:8952-8956.
7. Davis JE, Xie X, Guo J, Huang W, Chu WM, Huang S, Teng Y, Wu G. ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling. Oncotarget. 2016; doi: 10.18632/oncotarget.9405.
8. Dong C, Li C, Wu G. Regulation of a(2B)-adrenergic receptor-mediated extracellular signal-regulated kinase 1/2 (ERK1/2) activation by ADP-ribosylation factor 1. J Biol Chem. 2011; 286:43361-43369.
9. Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell. 2007; 129:865-877.
10. Bernards A, Settleman J. GAP control: regulating the regulators of small GTPases. J Cell Biol. 2004; 14:377-385.
11. Palacios F, Tushir JS, Fujita Y, D'Souza-Schorey C. Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell-cell adhesion during epithelial to mesenchymal transitions. Mol Biol Cell. 2005; 25:389-402.
12. Hashimoto A, Oikawa T, Hashimoto S, Sugino H, Yoshikawa A, Otsuka Y, Handa H, Onodera Y, Nam JM, Oneyama C, Okada M, Fukuda M, Sabe H, et al. P53-and mevalonate pathway-driven malignancies require Arf6 for metastasis and drugresistance. J Biol Chem. 2016; 213:81-95.
13. Cohen LA, Honda A, Varnai P, Brown FD, Balla T, Donaldson JG. Active Arf6 recruits ARNO/cytohesin GEFs to the PM by binding their PH domains. Mol Biol Cell. 2007; 18:2244-2253.
14. Boulay PL, Cotton M, Melançon P, Claing A. ADPribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells. The J Biol Chem. 2008; 283:36425-36434.
15. Boulay PL, Schlienger S, Lewis-Saravalli S, Vitale N, Ferbeyre G, Claing A. ARF1 controls proliferation of breast cancer cells by regulating the retinoblastoma protein. Oncogene. 2011; 30:3846-3861.
16. Lewis-Saravalli S, Campbell S, Claing A. ARF1 controls Rac1 signaling to regulate migration of MDA-MB-231 invasive breast cancer cells. Cell Signal. 2013; 25:1813-1819.
17. Schlienger S, Ramirez RA, Claing A. ARF1 regulates adhesion of MDA-MB-231 invasive breast cancer cells through formation of focal adhesions. Cell Signal 2015; 27:403-415.
18. Haines E, Schlienger S, Claing A. The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors. Cancer Biol Ther. 2015; 16:1535-1547.
19. Teng Y, Xie X, Walker S, White DT, Mumm JS, Cowell JK. Evaluating human cancer cell metastasis in zebrafish. BMC Cancer. 2013; 13:453.
20. Shao J, Teng Y, Padia R, Hong S, Noh H, Xie X, Mumm JS, Dong Z, Ding HF, Cowell J, Kim J, Han J, Huang S, et al. COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis. Neoplasia. 2013; 15:1075-1085.
21. Hong S, Noh H, Teng Y, Shao J, Rehmani H, Ding HF, Dong Z, Su SB, Shi H, Kim J, Huang S. SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells. Neoplasia. 2014; 16:279-290.
22. Viaud J, Zeghouf M, Barelli H, Zeeh JC, Padilla A, Guibert B, Chardin P, Royer CA, Cherfils J, Chavanieu A. Structure-based discovery of an inhibitor of Arf activation by Sec7 domains through targeting of proteinprotein complexes. Proc Natl Acad Sci USA. 2007; 104:10370-10375.
23. Flisiak S, Zeeh JC, Guibert B, Cherfils J, Zeghouf M. An Arf1 GTPase mutant with different responses to GEF inhibitors. Biochemical and Biochem Biophys Res Commun. 2008; 377:156-160.
24. Xie X, Ross JL, Cowell JK, Teng Y. The promise of zebrafish as a chemical screening tool in cancer therapy. Future Med Chem. 2015; 7:1395-1405.
25. Donaldson JG, Jackson CL. ARF family G proteins and their regulators: roles in membrane transport, development and disease. Nat Rev Mol Cell Biol. 2011; 12:362-375.
26. Schlienger S, Campbell S, Pasquin S, Gaboury L, Claing A. ADP-ribosylation factor 1 expression regulates epithelialmesenchymal transition and predicts poor clinical outcome in triple-negative breast cancer. Oncotarget. 2016; 7:15811-15827. doi: 10.18632/oncotarget.7515.
27. Simmons JK, Hildreth BE, Supsavhad W, Elshafae SM, Hassan BB, Dirksen WP, Toribio RE, Rosol TJ. Animal Models of Bone Metastasis. Vet Pathol. 2015; 52:827-41.
28. Teng Y, Ren X, Li H, Shull A, Kim J, Cowell JK. Mitochondrial ATAD3A combines with GRP78 to regulate the WASF3 metastasis-promoting protein. Oncogene. 2016; 35:333-343.
29. Eckert LB, Repasky GA, Ulkü AS, McFall A, Zhou H, Sartor CI, Der CJ. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res. 2004; 64:4585-4592.
30. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR. Ras activation in human breast cancer. Breast Cancer Res Treat. 2000; 62:51-62.
31. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem. 2011; 3:1787-1808.
32. Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer. 2011; 2:359-372. doi: 10.1177/1947601911412376.
33. Carracedo A, Ma L, Teruya-Feldstein, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008; 118:3065-3074.
34. Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA, et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest. 2011; 121:4311-4321.
35. Floc'h N, Kinkade CW, Kobayashi T, Aytes A, Lefebvre C, Mitrofanova A, Cardiff RD, Califano A, Shen MM, Abate-Shen C. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res. 2012; 72:4483-4493.
36. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA. MEK inhibition leads to PI3K/ AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012; 72:3228-3237.
37. Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, et al. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res. 2012; 18:5290-5303.
38. Shin HW, Nakayama K. Guanine nucleotide-exchange factors for arf GTPases: their diverse functions in membrane traffic. J Biochem. 2004; 136:761-767.
39. Cherfils J, Ménétrey J, Mathieu M, Le Bras G, Robineau S, Béraud-Dufour S, Antonny B, Chardin P. Structure of the Sec7 domain of the Arf exchange factor ARNO. Nature. 1998; 392:101-105.
40. Honda A, Al-Awar OS, Hay JC, Donaldson JG. Targeting of Arf-1 to the early Golgi by membrin, an ER-Golgi SNARE. J Cell Biol. 2005; 168:1039-1051.
41. Bourgoin SG, El Azreq MA. Small inhibitors of ADPribosylation factor activation and function in mammalian cells. World J Pharmacol. 2012; 1:55-64.
42. Ohashi Y, Iijima H, Yamaotsu N, Yamazaki K, Sato S, Okamura M, Sugimoto K, Dan S, Hirono S, Yamori T. AMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy. J Biol Chem. 2012; 287:3885-3897.
43. Feitsma H, Cuppen E. Zebrafish as a cancer model. Mol Cancer Res. 2008; 6:685-694.
44. Patton EE. Live imaging in zebrafish reveals neu(trophil) insight into the metastatic niche. J Pathol. 2012; 227:381-384.
45. Teng Y, Mei Y, Hawthorn LA, Cowell JK. WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells. Oncogene. 2014; 33:203-211.
46. Teng Y, Bahassan A, Dong D, Hanold LE, Ren X, Kennedy EJ, Cowell JK. Targeting the WASF3-CYFIP1 complex using stapled peptides suppresses cancer cell invasion. Cancer Res. 2016; 76:965-973.
47. Teng Y, Pi W, Wang Y, Cowell JK. WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling. Oncogene. 2016; doi: 10.1038/onc.2015.527.
48. Teng Y, Xie X, Walker S, Rempala G, Kozlowski DJ, Mumm JS, Cowell JK. Knockdown of zebrafish Lgi1a results in abnormal development, brain defects and a seizure-like behavioral phenotype. Hum Mol Genet. 2010; 19:4409-4420.
49. Teng Y, Xie X, Walker S, Saxena M, Kozlowski DJ, Mumm JS, Cowell JK. Loss of zebrafish lgi1b leads to hydrocephalus and sensitization to pentylenetetrazol induced seizure-like behavior. PLoS One. 2011; 6:e24596.
50. Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010; 123:725-731.